Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.38 |
| ▸ | DDX3X | O00571 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20438736 | 0.84 | CYP19A1 (0.36) | CYP19A1DDX3XNOS3NOS1NOS2 | |
| SCHEMBL22856966 | 0.84 | CYP19A1 (0.36) | CYP19A1DDX3XNOS3NOS1NOS2 | |
| SCHEMBL20711257 | 0.84 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL7651892 | 0.81 | CYP19A1 (0.42) | CYP19A1 | |
| SCHEMBL17886112 | 0.80 | CYP19A1 (0.42) | CYP19A1DDX3XNOS3NOS1NOS2 | |
| SCHEMBL20225135 | 0.80 | CYP19A1 (0.33) | CYP19A1DDX3X | |
| SCHEMBL23811156 | 0.79 | CYP19A1 (0.38) | CYP19A1ITGB2ICAM1ITGAL | |
| SCHEMBL20729505 | 0.79 | NOTUM (0.43) | CYP19A1 | |
| SCHEMBL12364357 | 0.79 | CYP19A1 (0.38) | CYP19A1 | |
| SCHEMBL16884145 | 0.79 | NOTUM (0.44) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827703-B2 | Compositions and methods related to anti-CD19 antibody drug conjugates | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-11814341-B2 | Non-peptidic cell-penetrating motifs | OHIO STATE INNOVATION FOUNDATION (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023194414-A1 | POLYDOPAMINE CO-POLYMER NANOPARTICLES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-10-12 | — | — | WO | disclosed |
| US-20230270868-A1 | PYRROLOBENZODIAZEPINE DIMER PRODRUG AND LIGAND-LINKER CONJUGATE COMPOUND OF THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2023-08-31 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11707533-B2 | Antibody-drug conjugate comprising antibody against human ROR1 and use for the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-07-25 | — | — | US | disclosed |
| US-20170095576-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-04-06 | — | — | US | disclosed |
| US-20170088614-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-03-30 | — | — | US | disclosed |
| US-20170088621-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-EGFR ANTIBODY DRUG CONJUGATES | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-03-30 | — | — | US | disclosed |
| US-20160333068-A1 | COMPOSITIONS AND METHODS FOR IMAGING CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2016-11-17 | — | — | US | disclosed |
| US-20160184451-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | LIGACHEM BIOSCIENCES INC. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-8198364-B2 | Poly (vinyl alcohol) polymers, uses and preparation thereof | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2012-06-12 | — | — | US | disclosed |
| US-8183264-B2 | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same | Eisai R&D Managment Co., Ltd. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100038297-A1 | Poly (Vinyl Alcohol) Polymers, Uses and Preparation Thereof | UNIVERSITE DE MONTREAL (CA) | 2010-02-18 | — | — | US | disclosed |
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | CYP19A1 4068/4885DDX3X 2814/4885NOS3 4879/4885 |
| US-11707533-B2 | Antibody-drug conjugate comprising antibody against human ROR1 and use for the same | RORA, RORB, RORC | CYP19A1 961/4885DDX3X 2779/4885NOS3 4822/4885 |
| US-20170088621-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | CYP19A1 793/4885DDX3X 4169/4885NOS3 1055/4885 |
| US-20160184451-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | IAPP, IDE, DNPEP | CYP19A1 4142/4885DDX3X 2353/4885NOS3 3310/4885 |
| US-20170088614-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES | CD47, CD22, BCL6 | CYP19A1 326/4885DDX3X 2413/4885NOS3 973/4885 |
| US-11814341-B2 | Non-peptidic cell-penetrating motifs | TIMM50, TIMM10, PITRM1 | CYP19A1 4637/4885DDX3X 996/4885NOS3 3325/4885 |
| US-20170095576-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | IAPP, IDE, DNPEP | CYP19A1 4398/4885DDX3X 1490/4885NOS3 3984/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | CYP19A1 2307/4885DDX3X 917/4885NOS3 1948/4885 |
| US-20100038297-A1 | Poly (Vinyl Alcohol) Polymers, Uses and Preparation Thereof | PUF60, VCL, PARG | CYP19A1 3140/4885DDX3X 3677/4885NOS3 2713/4885 |
| US-20160333068-A1 | COMPOSITIONS AND METHODS FOR IMAGING CANCER | SSTR1, SSTR3, SSTR5 | CYP19A1 853/4885DDX3X 2175/4885NOS3 2564/4885 |
| US-11827703-B2 | Compositions and methods related to anti-CD19 antibody drug conjugates | CD22, CD47, BCR | CYP19A1 1188/4885DDX3X 1648/4885NOS3 4424/4885 |
| US-20230270868-A1 | PYRROLOBENZODIAZEPINE DIMER PRODRUG AND LIGAND-LINKER CONJUGATE COMPOUND OF THE SAME | BCR, PIN1, PAICS | CYP19A1 553/4885DDX3X 4431/4885NOS3 4597/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | CYP19A1 4765/4885DDX3X 2893/4885NOS3 4760/4885 |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | ERG28, CBR3, CBR1 | CYP19A1 1649/4885DDX3X 4068/4885NOS3 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.